Skip to content
- Founded in 2021, ImmunAdd, Inc., is a privately held biopharmaceutical company on a mission to improve health through advances in adjuvant design and formulation.
- We are developing next generation saponin adjuvants and using them as the basis for new combination adjuvants and adjuvanted vaccines.
- Our lead adjuvant, IA05, is a rationally designed analogue of the saponin adjuvant QS-21. IA05 elicits immune responses comparable to or better than QS-21 and is better tolerated and more stable.
- With IA05 as the foundation, ImmunAdd is designing adjuvant platforms able to deliver a specific immune response .